Form 4: Acrivon Therapeutics Director Acquires Stock Options

Charles M. Baum, a director of Acrivon Therapeutics, acquired 20,275 stock options on June 20, 2024, at an exercise price of $6.52.

Summary

• On June 20, 2024, Charles M. Baum, a director of Acrivon Therapeutics, acquired 20,275 stock options.
• The exercise price of these options is $6.52.
• The options vest on the date immediately preceding the Issuer's next annual meeting of stockholders, contingent upon continuous service.
• Following the transaction, Baum directly owns 20,275 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition by a director.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the transactions of company directors and officers.

Stakeholder Impact

• The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.

Key Dates